Dissolvable nose implant shows promise for easier breathing

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non-calcified, mobile cartilaginous septal deviation. * ≥21 years of age. * Willing and able to provide informed consent and comply with the study protocol. * Seeking treatment for nasal airway obstruction (NAO) due to septal deviation and is willing to undergo a nasal implant procedure. * Type I, II, or III septal deviation as defined by 7-Degree Mladina classification scheme * NOSE score ≥30 at Screening Visit. * Appropriate nasal anatomy to receive the implant(s). Exclusion Criteria: * Type IV, V, VI or VII septal deviation as defined by 7-Degree Mladina classification scheme (See Table 2) or other non-cartilaginous septum anatomical pathology identified on CT scan suspected by Investigator to be the primary contributor to NAO. * Having a concurrent ENT procedure, other than turbinate reduction. * Previous septoplasty or rhinoplasty. * Has had turbinate reduction or other nasal surgeries within the past six (6) months. * Plans to have any surgical or non-surgical treatment of their nasal septum, other than the index procedure, within six (6) months of the procedure. * Permanent implant or dilator in the nasal area. * Concomitant autoimmune, inflammatory, or infectious skin conditions, unhealed wounds, septal perforation, or mucosal irregularities in the treatment area. * Currently has active nasal vestibulitis or folliculitis. * History of nasal vasculitis. * Current or chronic systemic steroid and/or recreational intra-nasal drug user. * Has had a cancerous or pre-cancerous lesion and/or has had radiation exposure in the treatment area or active chemotherapy. * Polyps or pathology, other than turbinate hypertrophy, that may be primary contributor to airway obstruction, in the opinion of the investigator. * History of a significant bleeding disorder(s) and/or current prescription blood thinner medication that would prevent healing of the treatment area post procedure. * Known or suspected allergy to polydioxanone or other absorbable materials. * Significant systemic disease such as poorly controlled diabetes or connective tissue disease which, in the investigator's opinion, could pre-dispose the participant to poor wound healing. * Current tobacco or tobacco-related product use or history within the past 10 years of heavy smoking (on average, more than half a pack of cigarettes per day). * Female participants of childbearing potential who are known or suspected to be pregnant and/or lactating. * Any physical condition that, in the Investigator's opinion, would prevent adequate study participation or increase risk. * Additionally, for OR cases (Cohorts 1 or 3) any individual who meets the following criteria will be ineligible for enrollment as an OR case * Is not a candidate for procedures conducted under general anesthesia. * Additionally, for in-office cases (Cohort 2) any individual who meets the following criteria will be ineligible for enrollment as an in-office case: * s not a candidate for procedures conducted under local anesthesia alone.